Latest / Community Health Media
ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton
How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer?
Dr. Jason Mouabbi and Dr. Erika Hamilton discuss the evolving treatment landscape for hormone receptor-positive, HER2-negative metastatic breast cancer, with a focus on ESR1 mutations, molecular testing, PROTACs, oral SERDs, and treatment sequencing.
They explore when and how to test for ESR1 mutations, including the role of liquid biopsy and serial testing as resistance emerges. The conversation also examines the differences between a PROTAC and oral SERDs, the clinical data…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.